SEP
CSTL icon

Signature Equity Partners’s Castle Biosciences CSTL Stock Holding History

Signature Equity Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393 Hold
16
– – ﹤0.01% 1410
2025
Q4 		$622 Buy
+16
New +$516 ﹤0.01% 1497

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Signature Equity Partners's CSTL Position: Q1 2026 in Review

Signature Equity Partners held its Castle Biosciences (CSTL) position steady in Q1 2026 at 16 shares worth $393. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Signature Equity Partners first reported a position in CSTL in Q4 2025 and has held it in 2 quarters since. The position peaked at $622 in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Signature Equity Partners held 16 shares of Castle Biosciences worth $393 as of Q1 2026.
  • Signature Equity Partners left its Castle Biosciences share count unchanged in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of Signature Equity Partners's portfolio in Q1 2026, its #1410 holding.
  • Signature Equity Partners first reported a position in Castle Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's Castle Biosciences position peaked at $622 in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.